Article info
PDFRespiratory medicine: common problems, new insights
P71 Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one centre’s experience
Citation
P71 Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one centre’s experience
Publication history
- First published November 15, 2017.
Online issue publication
September 01, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions